613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

• Jae Ho Byun,
• Jeeyun Lee,
• Kyong Hwa Park,
• Eun Joo Kang,
• In Gyu Hwang,
• Ju Won Kim,
• Hyo Jin Lee,
• Ji Yoon Lee,
• Jason K Sa,
• Sook Ryun Park,
• Yu Kim,
• Woo Kyun Bae,
• Jung Sun Kim,
• Sang Shin

Affiliations

Jae Ho Byun

8The Catholic University of Korea Incheon St. Mary’s Hospital, Incheon, Republic of Korea

Jeeyun Lee

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Kyong Hwa Park

1Korea University Anam Hospital, Seoul, Republic of Korea

Eun Joo Kang

14 Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

In Gyu Hwang

Internal Medicine, Chung-Ang University College of Medicine, Dongjak-gu, Seoul, Korea

Ju Won Kim

1Korea University Anam Hospital, Seoul, Republic of Korea

Hyo Jin Lee

2Chungnam National University Hospital, Daejeon, Republic of Korea

Ji Yoon Lee

3Korea University College of Medicine, Seoul, Republic of Korea

Jason K Sa

3Korea University College of Medicine, Seoul, Republic of Korea

Sook Ryun Park

4Asan Medical Center, Seoul, Republic of Korea

Yu Kim

5Seoul National University Bundang Hospital, Seongnam, Korea, Republic of Korea

Woo Kyun Bae

7Chonnam National Univertisy Medical School and Hwasun Hospital, Hwasun, Republic of Korea

Jung Sun Kim

9Korea University Ansan Hospital, Ansan, Republic of Korea

Sang Shin

12Yonsei Cancer Center, Seoul, Republic of Korea